Menopausal hormone therapy has long carried a boxed warning (formerly a "black box warning") that may not accurately reflect the therapy's risk-benefit profile for all patients. This course discusses the FDA's recent removal of boxed warnings for select hormone therapy (HT) products, the rationale for this change, and how evolving guidance may impact patient care. You will explore strategies to support evidence-based counseling and individualized decision-making for patients considering HT.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Erin Raney, PharmD
Professor
Midwestern University College of Pharmacy

GAMECHANGERS CLINICAL UPDATE SERIES
The Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. 

PRACTICE RESOURCE
Purchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.

 
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here. 

 CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize the FDA's updated position on boxed warnings for menopausal hormone therapy.
2. Identify key considerations for pharmacists when counseling patients about the benefits and risks of hormone therapy.

Rachel Maynard and Erin Raney have no relevant financial relationships with ineligible companies to disclose.

0.075 CEU/0.75 Hr
UAN: 0107-0000-26-044-H01-P
Initial release date: 1/26/2026
Expiration date: 1/26/2027
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Follow CEimpact on Social Media:
LinkedIn
Instagram